Tirzepatide
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-TIRZEPATIDE |
|---|---|
| Type | Drug |
| Aliases | MounjaroZepboundТирзепатид |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Dual GIP and GLP-1 receptor agonist (once-weekly) |
|---|---|
| Mechanism | Synthetic 39-amino-acid peptide that activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. Dual agonism produces greater glycemic control and weight loss than GLP-1 monoagonism. At obesity dose (max 15 mg weekly), SURMOUNT-1 trial demonstrated ~21% mean weight loss vs ~3% on placebo — superior to semaglutide 2.4 mg. Obesity is associated with 13+ cancers (IARC/WCRF) — sustained weight loss is a cancer-prevention intervention. |
| Typical dosing | SC: dose escalation over ≥20 weeks to maximize tolerability: Week 1-4: 2.5 mg SC weekly Week 5-8: 5 mg SC weekly Week 9-12: 7.5 mg SC weekly Week 13-16: 10 mg SC weekly Week 17-20: 12.5 mg SC weekly Week 21 onward: 15 mg SC weekly (maximum obesity dose) Inject SC abdomen / thigh / upper arm any day of the week; rotate sites. Lower maintenance doses (5, 10, 15 mg) acceptable based on response/tolerance. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-05-18 |
Warnings
- Risk of thyroid C-cell tumors — rodent carcinogenicity studies showed dose-dependent MTC and C-cell hyperplasia (class effect with GLP-1 RAs)
Notes
STUB — v0.2 prevention-workstream authoring; pending two-Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode. Zepbound (tirzepatide 15 mg max) is the most effective approved obesity pharmacotherapy as of 2026 (~21% weight loss SURMOUNT-1). Dual GIP+GLP-1 mechanism. Obesity is associated with 13+ cancers per IARC/WCRF — pharmacotherapy is a recognized component of weight-loss strategy when behavioral approaches fail. Source cited is closest in-KB until USPSTF/AACE/WCRF obesity- pharmacotherapy sources land in source-stub workstream.
Used By
Contraindications
CI-SEMAGLUTIDE-MEN2-MTC- CI-SEMAGLUTIDE-MEN2-MTC
Regimens
REG-TIRZEPATIDE-OBESITY- Tirzepatide 15 mg weekly for chronic obesity management